Celularity (CELUW) Non-Current Deffered Revenue (2019 - 2025)
Celularity (CELUW) reported Non-Current Deffered Revenue of $2.8 million for Q4 2025, up 2.75% year-over-year from $2.7 million in Q4 2024, and up 1.27% quarter-over-quarter from $2.8 million in Q3 2025.
Celularity (CELUW) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Celularity (CELUW) has 7 years of Non-Current Deffered Revenue data on file, last reported at $2.8 million in Q4 2025.
- Non-Current Deffered Revenue for Q4 2025 came in at $2.8 million, up 2.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.8 million (up 2.75% YoY), and the FY2025 annual result was $2.8 million, up 2.75% from the prior year.
- Non-Current Deffered Revenue climbed to $2.8 million in Q4 2025 per CELUW's latest filing, from $2.8 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $10.8 million in Q1 2021 and troughed at $1.8 million in Q3 2021.
- A 5-year average of $3.4 million and a median of $2.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue plunged 83.51% in 2021, then surged 46.18% in 2023.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $1.9 million in 2021, then increased by 18.6% to $2.2 million in 2022, then jumped by 43.58% to $3.2 million in 2023, then dropped by 14.5% to $2.7 million in 2024, then increased by 2.75% to $2.8 million in 2025.
- Business Quant data shows CELUW's Non-Current Deffered Revenue at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Celularity | - | - | -3.27 Mn | 2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.80 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 3.44 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.10 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Sep 30, 2021 | 1.78 Mn |
| Jun 30, 2021 | 10.81 Mn |
| Mar 31, 2021 | 10.81 Mn |